Cantor Fitzgerald Predicts Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Ardelyx in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will earn ($0.13) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share.

A number of other equities analysts have also recently issued reports on ARDX. Piper Sandler upped their target price on Ardelyx from $7.00 to $8.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. HC Wainwright reaffirmed a "neutral" rating and issued a $5.50 price objective on shares of Ardelyx in a research note on Friday, February 21st. BTIG Research assumed coverage on shares of Ardelyx in a research report on Tuesday, March 4th. They set a "buy" rating and a $14.00 target price on the stock. Scotiabank initiated coverage on shares of Ardelyx in a research report on Friday. They issued a "sector outperform" rating and a $15.00 price target for the company. Finally, LADENBURG THALM/SH SH reaffirmed a "buy" rating and set a $11.00 price target on shares of Ardelyx in a research note on Friday. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Ardelyx presently has a consensus rating of "Moderate Buy" and an average target price of $10.95.

Remove Ads

Ardelyx Price Performance

Shares of NASDAQ:ARDX traded down $0.06 during trading on Thursday, hitting $5.24. 2,431,158 shares of the company were exchanged, compared to its average volume of 4,397,617. The company has a quick ratio of 4.31, a current ratio of 4.58 and a debt-to-equity ratio of 0.87. Ardelyx has a 1-year low of $4.32 and a 1-year high of $9.33. The company has a market capitalization of $1.25 billion, a P/E ratio of -32.75 and a beta of 0.87. The business's 50 day moving average is $5.39 and its 200-day moving average is $5.59.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, hitting analysts' consensus estimates of $0.02. The company had revenue of $116.13 million for the quarter, compared to analysts' expectations of $111.16 million. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%.

Insider Activity

In other news, insider Laura A. Williams sold 4,941 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $5.62, for a total value of $27,768.42. Following the completion of the sale, the insider now directly owns 303,804 shares in the company, valued at $1,707,378.48. This trade represents a 1.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael Raab sold 25,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $5.26, for a total value of $131,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,150,385 shares of the company's stock, valued at $6,051,025.10. The trade was a 2.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 490,029 shares of company stock valued at $2,377,766 and have sold 183,076 shares valued at $985,304. 5.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ardelyx

A number of hedge funds have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc increased its stake in Ardelyx by 3.1% during the 4th quarter. Ensign Peak Advisors Inc now owns 73,950 shares of the biopharmaceutical company's stock valued at $375,000 after purchasing an additional 2,200 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its position in Ardelyx by 3.4% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 90,000 shares of the biopharmaceutical company's stock valued at $599,000 after acquiring an additional 3,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Ardelyx by 2.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 154,625 shares of the biopharmaceutical company's stock valued at $788,000 after acquiring an additional 3,550 shares in the last quarter. Swiss National Bank boosted its stake in Ardelyx by 1.0% during the 4th quarter. Swiss National Bank now owns 463,100 shares of the biopharmaceutical company's stock valued at $2,348,000 after purchasing an additional 4,800 shares during the last quarter. Finally, Orion Portfolio Solutions LLC increased its holdings in Ardelyx by 42.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company's stock worth $84,000 after purchasing an additional 4,933 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company's stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.